MedicalCV Announces Addition of Industry Experts to ATRILAZE(TM) Research & Development Team Company Takes Proactive Steps to Enhance Strategic Growth MINNEAPOLIS, May 26 /PRNewswire-FirstCall/ -- MedicalCV, Inc. (OTC:MDCV) (BULLETIN BOARD: MDCV) , http://www.medcvinc.com/ , a cardiovascular surgery device manufacturer, announced today the addition of Gregory G. Brucker, Ph.D., and Kenneth W. Grace, Ph.D. to the research & development team. "Dr. Brucker is a highly-respected expert in the field of laser physics. As our Principal Scientist, he brings over 15 years of experience working with laser energy and 20 years of experience in the development of medical devices," said Adam L. Berman, Vice President of Research & Development. "His expertise in arrhythmia ablation technologies will be invaluable in our ongoing product development and market validation initiatives." "Dr. Grace has over 16 years of experience in the design of complex robotic systems and micromanipulators applied to cardiac and ophthalmic surgery. As our Principal Design Engineer, Dr. Grace will be instrumental in the development and evolution of laser delivery mechanisms for the stand- alone, minimally invasive (closed-chest, beating heart) surgical procedure of the future," continued Berman. "The addition of these two highly qualified individuals to the research & development team is a testament to the strong scientific foundation being established at MedicalCV. We are excited by the addition of such strong talent as the market validates that coherent laser is the "ideal" energy source for cardiac tissue ablation as a potential means to treat atrial fibrillation," said Marc P. Flores, President and CEO. About MedicalCV, Inc. MedicalCV, Inc., a cardiovascular surgery device manufacturer, which focuses on the development and introduction of products designed to improve patient outcomes through the early treatment of cardiovascular disorders and disease specifically, products used by cardiac surgeons to ablate cardiac tissue as a potential means to treat atrial fibrillation. The Company's core technology is the ATRILAZE(TM) Surgical Ablation System for use in cardiac tissue ablation procedures in open-heart surgery. The Company acquired this technology in August 2003 and received its FDA 510(k) clearance in November 2004. The ATRILAZE(TM) system is now available commercially for concomitant open-heart surgical procedures. The Company's common stock is traded on the OTC Bulletin Board under the symbol "MDCV." For further information on MedicalCV, Inc., please visit http://www.medcvinc.com/ . You may register to receive MedicalCV's future press releases and to be added to the Company's distribution list by visiting: http://www.roiny.com/form.php . This release contains certain forward-looking statements of expected future developments, as defined in the Private Securities Litigation Reform Act of 1995. The forward-looking statements in this release refer to our expectations regarding disposition of our heart valve business, operating improvements, development of atrial fibrillation product and minimally invasive treatment of atrial fibrillation. These forward-looking statements reflect management's expectations and are based on currently available data; however, actual results are subject to future risks and uncertainties, which could materially affect actual performance. Risks and uncertainties that could affect such performance include, but are not limited to, the following: the Company's ability to fund significant capital needs; market acceptance in the U.S. of the Company's cardiovascular products; acceptance of minimally invasive techniques for the reduction of atrial fibrillation through ablation; potential reductions in pricing by competitors; the costs of licensing and acquiring new products and technologies; the time and costs involved in obtaining regulatory clearance for cardiovascular products; competing technological and market developments; physician acceptance of the Company's cardiovascular products; dependence upon governmental reimbursements and third party supplies; and the strength of the market for cardiovascular products. For more detailed information about these risks and uncertainties, please review the Company's Annual Report on Form 10- KSB for the fiscal year ended April 30, 2004 and our 8-K report filed with the Securities and Exchange Commission on May 17, 2005 These events and uncertainties are difficult or impossible to predict accurately and many are beyond the Company's control. The Company assumes no obligation to publicly release the results of any revisions that may be made to any forward-looking statements to reflect events or uncertainties after the date of such statements or to reflect the occurrence of anticipated or unanticipated events. DATASOURCE: MedicalCV, Inc. CONTACT: Adam L. Berman, Vice President, Research & Development of MedicalCV, Inc., +1-651-452-3000, , or Investors: Robert Giordano, President, +1-212-495-0200, ext. 10, , or Sarah Shepard, Vice President, +1-212-495-0200, ext. 17, , both of ROI Group Associates, Inc. Web site: http://www.roiny.com/form.php http://www.medcvinc.com/

Copyright